Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Organogenesis Prepares To Restructure In The Face Of New CMS Skin-Substitute Policy

This article was originally published in The Pink Sheet Daily

Executive Summary

The maker of Apligraf for foot ulcers and venous leg ulcers is facing a more than 30% reduction in Medicare reimbursement starting Jan. 1. Organogenesis’ CEO says the firm is readying a plan to significantly trim its business costs so it can continue to market the PMA-approved, bioengineered product.

You may also be interested in...

Louis Jacques On Coverage, Evidence And IDEs

Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.

Reimbursement Briefs: Pfizer Joins Big Data Group; Part D Protected Classes; Wikipedia Partners With Cochrane Collaboration

Pfizer is among seven organizations joining the Optum Labs research collaborative; CMS Coverage and Analysis Group Director Louis Jacques moving to private sector, more news in brief.

CMS Lessens Lab Test Cuts, Finalizes Revaluation Proposal In Physician Fee Schedule

In the final 2014 physician fee schedule rule, CMS scaled back cuts to independent labs from 26 percent to 5 percent. But it moved ahead with its proposal to update individual lab payments based on technological changes, a move that might lead to reductions over the long term.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts